Chemotherapy de-escalation using an 18F-FDG-PET-based pathological response-adapted strategy in patients with HER2-positive early breast cancer (PHERGain): a multicentre, randomised, open-label, non-comparative, phase 2 trial

1. Pérez-García, J.M.
2. Gebhart, G.
3. Ruiz Borrego, M.
4. Stradella, A.
5. Bermejo, B.
6. Schmid, P.
7. Marmé, F.
8. Escrivá-de-Romani, S.
9. Calvo, L.
10. Ribelles, N.
11. Martinez, N.
12. Albacar, C.
13. Prat, A.
14. Dalenc, F.
15. Kerrou, K.
16. Colleoni, M.
17. Afonso, N.
18. Di Cosimo, S.
19. Sampayo-Cordero, M.
20. Malfettone, A.
21. Cortés, J.
22. Llombart-Cussac, A.